Table 4 Stratified analysis of melanoma recurrence risk by type of immunotherapy (immune biologics and vaccines) in the patients who had primary adjuvant immunotherapy
| Â | MMP-23 composite score | |||
|---|---|---|---|---|
Immune biologicsa | Vaccinesb | |||
0 - 2 | 3 - 4 | 0 - 2 | 3 - 4 | |
Recurrence | Â | Â | Â | Â |
Yes | 1 (25%) | 13 (87%) | 4 (57%) | 10 (71%) |
No | 3 (75%) | 2 (23%) | 3 (43%) | 4 (29%) |
Total | 4 (100%) | 15 (100%) | 7 (100%) | 14 (100%) |